The European Medicines Agency (EMA) granted PRIME Designation to GSK’227, a B7-H3-targeted antibody-drug conjugate (ADC) for treating relapsed extensive-stage small-cell lung cancer (ES-SCLC), based on promising preliminary clinical data

GSK’227 is currently being evaluated in the ARTEMIS-001 phase I study, which involves over 200 patients with various solid tumors, including relapsed ES-SCLC

Small-cell lung cancer (SCLC) is a highly aggressive cancer, with extensive-stage (ES) cases accounting for a large proportion and having a very poor prognosis, especially for platinum-resistant patients

GSK acquired exclusive worldwide rights (excluding China) from Hansoh Pharma to develop and commercialize GSK’227 for the treatment of ES-SCLC and other tumors